Amatuximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Amatuximab ?
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target mesothelin
Clinical data
Legal status
?
Identifiers
CAS number 931402-35-6 N
ATC code None
Chemical data
Formula C6394H9870N1694O2024S46 
Mol. mass 144.33 kDa (peptide)
 N (what is this?)  (verify)

Amatuximab is a chimeric monoclonal antibody designed for the treatment of cancer.[1]

Amatuximab was developed by Morphotek, Inc.

Amatuximab is also known as Anti-mesothelin monoclonal antibody MORAb-009. Amatuximab is an anti-mesothelin monoclonal antibody MORAb-009 binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing, and also called MORAb-009.[citation needed]

References[edit]